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Abstract
Background: Phenylketonuria (PKU; OMIM#261600) is a rare metabolic disorder caused by mutations in the
phenylalanine hydroxylase (PAH) gene resulting in high phenylalanine (Phe) in blood and brain. If not treated early
this results in intellectual disability, behavioral and psychiatric problems, microcephaly, motor deficits, eczematous
rash, autism, seizures, and developmental problems. There is a controversial discussion of whether patients with
PKU have an additional risk for atherosclerosis due to interference of Phe with cholesterol synthesis and LDL-
cholesterol regulation. Since cholesterol also plays a role in membrane structure and myelination, better insight into
the clinical significance of the impact of Phe on lipoprotein metabolism is desirable. In 22 treated PKU patients
(mean age 38.7 years) and 14 healthy controls (mean age 35.2 years), we investigated plasma with NMR
spectroscopy and quantified 105 lipoprotein parameters (including lipoprotein subclasses) and 24 low molecular
weight parameters. Analysis was performed on a 600 MHz Bruker AVANCE IVDr spectrometer as previously
described.
Results: Concurrent plasma Phe in PKU patients showed a wide range with a mean of 899 μmol/L (50–1318 μmol/
L). Total cholesterol and LDL-cholesterol were significantly lower in PKU patients versus controls: 179.4 versus 200.9
mg/dL (p < 0.02) and 79.5 versus 104.1 mg/dL (p < 0.0038), respectively. PKU patients also had lower levels of 22
LDL subclasses with the greatest differences in LDL2 Apo-B, LDL2 Particle Number, LDL2-phospholipids, and LDL2-
cholesterol (p < 0.0001). There was a slight negative correlation of total cholesterol and LDL-cholesterol with
concurrent Phe level. VLDL5-free cholesterol, VLDL5-cholesterol, VLDL5-phospholipids, and VLDL4-free cholesterol
showed a significant (p < 0.05) negative correlation with concurrent Phe level. There was no difference in HDL and
their subclasses between PKU patients and controls. Tyrosine, glutamine, and creatinine were significantly lower in
PKU patients compared to controls, while citric and glutamic acids were significantly higher.
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Conclusions: Using NMR spectroscopy, a unique lipoprotein profile in PKU patients can be demonstrated which
mimics a non-atherogenic profile as seen in patients treated by statins.
Keywords: Adult PKU, Treatment, Cholesterol, Lipoprotein subclasses, NMR,
Background
Phenylketonuria (PKU; OMIM#261600) is a rare meta-
bolic disorder caused by mutations in the phenylalanine
hydroxylase (PAH) gene resulting in high phenylalanine
(Phe) in blood and brain. If not treated early this results
in intellectual disability, behavioral and psychiatric prob-
lems, microcephaly, motor deficits, eczematous rash,
autism, seizures, and developmental problems. Although
the PAH system converting Phe to tyrosine is well char-
acterized, the pathophysiology of PKU and the impact of
high Phe on the central nervous system is not well
understood. Most theories focus on neurotransmitter
depletion [1, 2], impaired brain protein synthesis [3, 4],
and oxidative stress leading to early cell death and im-
paired mitochondrial function [5, 6]. A possible role of
lipid metabolism was the focus of an investigation of es-
sential fatty acids and a deficiency caused by the special
PKU diet [7, 8]. A deficiency in cholesterol leading to
hypomyelination as a possible cause of intellectual dis-
ability has been considered, but studies in patients are
controversial and restricted to cholesterol measurements
as recently summarized in a systematic review [9].
None of these studies have used modern NMR meta-
bolomic lipoprotein profiling [10] as it is now widely
used, e.g. in studies demonstrating statin effects in pa-
tients with cardiovascular disease [11]. We therefore ap-
plied this metabolomic technique in 22 adult classical
PKU patients and 14 healthy age-matched controls. The
aim of the study was to characterize the spectrum of
cholesterol, LDL-cholesterol, HDL-cholesterol, lipopro-
tein subclasses, and low molecular weight parameters in
comparison to controls to give further insight into the
pathophysiology of brain damage in PKU [12]. In
addition, the results should elucidate a possible cardio-
vascular risk in PKU patients [13] caused by an abnor-
mal lipoprotein profile.
Patients and methods
We performed plasma lipoprotein analysis to quantify
105 lipoprotein subclasses and 24 low molecular weight
metabolites from the NMR spectra [10] in 22 treated
adult PKU patients (16 females and 6 males) (Table 1),
with a mean age of 38.7 (range 30–54) years, and a mean
body mass index (BMI) of 27.2 (range 20.7–51.3) kg/m2.
Controls (8 females and 6 males) had a mean age of 35.2
(range 30–45) years. Controls were also matched for so-
cial and educational level. BMI was slightly lower with a
mean of 23.9 (range 21.3–29.8) kg/m2. Two out of 22
patients with triglycerides of 475 and 625 mg/dL respect-
ively were excluded from lipoprotein evaluation. The
high triglycerides were assumed not to be related to
PKU or BMI (27.5 and 23.6 kg/m2, respectively). None
of the patients or controls displayed clinical symptoms
or medical histories indicating additional cardiovascular
investigations. All patients were told to follow a Phe-
restricted diet, but adherence to treatment recommenda-
tions was highly variable, yielding plasma Phe levels be-
tween 50 and 1318 μmol/L (mean 899). Plasma samples
were drawn in the morning after an overnight fast and
frozen at − 20 °C. Analysis was performed on a 600MHz
Bruker AVANCE IVDr spectrometer as previously de-
scribed [10, 14]. Statistical analysis was performed using
STATISTIKA.Ink. and SPSS 24.0.
Results
Lipoprotein subclasses
There were significantly lower levels of total and LDL-
cholesterol in PKU patients versus controls: 179.4 versus
200.9 mg/dL (p < 0.02) and 79.5 versus 104.1 mg/dL
(p < 0.003), respectively. Total triglycerides differed
widely among patients, but there was no difference be-
tween patients and controls (Complete list of results in
Table S2). Significant disparities were restricted to LDL
subclasses (Table 2) with the greatest differences in
LDL2 Apo-B, LDL2 Particle Number, LDL2-
phospholipids, and LDL2-cholesterol (p < 0.05). All other
lipoprotein subclasses did not show significant differ-
ences between patients and controls (p > 0.05). There
were no changes detectable in HDL and VLDL lipopro-
teins (Table S2). Adherence to diet did not correlate
with lipoproteins but did with blood Phe levels: a signifi-
cant negative correlation of plasma Phe with VLD5-
cholesterol, VLDL5-free cholesterol, VLDL5-
phospholipid, and VLDL5-triglyceride is shown in Fig. 1.
Partial correlation of plasma Phe corrected for the effect
of BMI with VLDL5-free cholesterol (R = -0.49.1, p =
0.024), VLDL5-triglycerides (R = -0.55, p = 0.009),
VLDL5-cholesterol (R = -0.54, p = 0.012), and VLDL5-
phospholipids (R = -0.58, p = 0.006) confirmed the nega-
tive impact of Phe on these VLDL subclasses. Choles-
terol and LDL-cholesterol also showed a negative
correlation to Phe; however, this was not statistically
significant.
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Low molecular weight metabolites
Low molecular weight metabolites besides Phe revealed
significant differences for the following metabolites
(PKU versus controls, Table 3): glutamine (611 versus
690 μmol/L, p < 0.01); creatinine (74.8 versus 86.1 μmol/
L, p < 0.01); and tyrosine (42.5 versus 56.9 μmol/L, p <
0.005). Glutamic acid as well as citric acid were signifi-
cantly higher in PKU patients versus controls: 87.6 ver-
sus 50.5 μmol/L (p < 0.015) and 186.9 versus 157.2 μmol/
L (p < 0.019), respectively.
BMI did not show a significant influence on the lipo-
protein subclasses in the patients investigated except
quality of dietary treatment; patients with higher BMI
had less optimal Phe control than those with a lower
BMI (Fig. 2).
Discussion
The data show an impact of Phe on lipoprotein concen-
tration in plasma indicating a negative influence on
cholesterol synthesis or LDL regulation. Animal models
have demonstrated decreases in 3-hydroxy-3-methylglu-
taryl-CoA reductase (HMGR) and mevalonate-5-
pyrophosphate decarboxylase in liver and brain by high
Phe [15] leading to impaired cholesterol synthesis. It was
speculated that this impairment may lead to hypomyeli-
nation and mental retardation in untreated PKU pa-
tients. Later on, it was shown that HMGR activity was
not impaired in the liver in a PAH (enu2) genetic mouse
model, but a reduction of HMGR activity by 40% was
found in oligodendrocytes of the forebrain in the hypo-
myelinated tracts [16]. In summary, there have been in-
consistent findings about the impact of Phe on
cholesterol concentration: 12 studies demonstrated
lower levels of cholesterol, while 6 studies did not, as re-
cently published in a systematic review by Montoya
Parra et al. [9].
There is a unique lipoprotein profile pattern in our PKU
patients compared to controls. Significant disparities are
limited to cholesterol, LDL-cholesterol, and LDL sub-
classes. Interpretation of the intergroup difference is
Table 1 Patient characteristics
ID Age Gender BMI Actual Phe μmol/L Allele 1 Allele 2 GPV1 Diet Adherence2
1 46 M 51.3 1318 p.R408W IVS12 + 1G > A 0 0
2 35 F 21.2 1183 p.R261Q IVS7 + 3 g > c 1.3 0
3 43 F 27 957 p.G239V IVS10–11 g > a n/a 1
4 45 M 26.8 1532 p.R158Q p.R158Q 0 0
5 44 F 25 796 p.L48S p.Y387H 2.4 1
6 30 F 21.8 402 n/a n/a n/a 1
7 45 M 23.3 730 p.R261Q p.G272X 1.3 1
8 32 M 23.1 1017 p.S349P p.L348V n/a 1
9 39 F 31.2 648 p.L48S p.R408W 2.4 1
10 42 F 21.3 51 p.P281L IVS12 + 1G > A 0 1
11 54 F 29.6 238 p.L48S IVS10–11 G > A 2.4 1
12 31 F 20.7 60 p.R158Q p.R158Q 0 1
13 33 F 32 1013 IVS12 + 1G > A IVS12 + 1G > A 0 0
14 38 F 41.8 1905 IVS10–11 g > a p.R408W 0 0
15 41 F 21.2 142 p.R158W p.R252Gfs*30 0 1
16 44 M 23.8 1409 p.P281L p.R408W 0 1
17 31 F 24.9 929 p.R408W IVS10-3C > T 0.9 1
18 45 F 22.4 349 p.R408W p.R408W 0 1
19 36 F 31.2 1106 p.R158Q p.R158Q 0 0
20 37 F 26.8 1207 p.F39L p.R252W 1.4 0
21 30 M 27.5 866 p.R261Q p.R408W 1.3 1
22 31 F 23.6 416 n/a n/a n/a 1
mean 38.7 27.2 899
BMI body mass index, GPV genetic predicted value, Phe plasma phenylalanine at time of investigation.
1(www.biopku.org): < 5 predicts classical PKU
2Adherence to diet: 1, yes; 0, no.
Adherence to the diet was evaluated on basis of the diet prescription provided by the patient. 1: regular intake of low protein food, daily intake of amino acid
Phe-free formula; 0: no intake of low protein food, irregular intake of amino acid formula
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difficult since there is only a small negative correlation of
Phe on total cholesterol and LDL-cholesterol, which is not
statistically significant (data not shown). In contrast, there
is a significant negative correlation between plasma Phe
and higher densities of VLDL subfractions (VLDL5 corre-
sponding to 1.006 kg/L) as shown in Fig. 1 A–D also when
corrected by BMI. Low cholesterol and LDL-cholesterol
have also been observed by Couce et al. [17] when com-
paring patients with hyperphenylalaninemia and classical
PKU. Since well-treated PKU patients are treated by a
vegan-like diet supplemented with an artificial Phe-free
amino acid mixture, dietary effects on the lipid pattern
cannot be excluded [9]. While HDL-cholesterol can be
lowered by a vegan diet, LDL-cholesterol levels are not in-
fluenced by a vegan diet [18]. However, in a meta-analysis
[19], it is evident that cholesterol, LDL-cholesterol and
HDL-cholesterol are reduced by a vegan diet. Our patients
with a less well-controlled diet leading to higher Phe levels
should have higher intakes of natural protein and there-
fore higher risks of elevated lipoproteins. As shown by the
extensive lipoprotein subclass analysis, they had lower
total cholesterol and LDL-cholesterol but not HDL-
cholesterol. This leads to the discussion of how cholesterol
and LDL-cholesterol may be influenced/decreased in PKU
patients.
Regulation of LDL-cholesterol is a complex mechan-
ism as demonstrated in a comprehensive review by
Goldstein and Brown [20]. Cells obtain cholesterol from
endogenous synthesis via HMG CoA, receptor-mediated
uptake, and lysosomal hydrolysis of LDL-cholesterol.
Statins reduce cholesterol synthesis by inhibition of
HMG-reductase activity. High Phe may mimic this statin
effect. Regulation of the LDL receptor gene is mediated
by sterol regulatory element-binding protein-1 (SREBP)
transcription factors. When entering the nucleus,
SREBPs also activate endogenous cholesterol biosyn-
thesis. A low cholesterol diet as present in PKU patients
may lead to activation of SREBPs which activate LDL re-
ceptor transcription and HMGR activity, thereby in-
creasing cholesterol synthesis and decreasing LDL [20].
Another player of LDL regulation is proprotein conver-
tase subtilisin/kexin type 9 (PCSK9) [21, 22]. Mutations
in the gene of this protein, which interferes with the
LDL receptor, may destroy the LDL receptor or partially
inactivate PCSK9, thus reducing plasma LDL levels. No
data are available demonstrating whether high Phe inter-
feres with this protein function. In summary, the LDL
lowering mechanism in PKU patients is unclear and
needs further investigation [9]. The statin-like effect of
high Phe may also be the cause of higher concentrations
of citrate and glutamic acid in patients compared to con-
trols, as inhibition of HMGR leads to an increase of
HMG-CoA which feeds acetyl CoA into the citric cycle.
The role of the vegan diet on lipoprotein profile in our
PKU patients cannot be totally excluded. However, a
negative impact of Phe on cholesterol, LDL-cholesterol,
VLDL-cholesterol (except HDL-cholesterol) and their
subclasses indicate a key role of elevated Phe on the
lipoprotein profile with great similarities to that seen in
patients with high cholesterol using statins [11].
Low molecular mass metabolites showed that in the
patients investigated there was no evidence of catabolism
as indicated (e.g. by elevated ketones). However, acetoa-
cetic and 3-OH-butyric acid tended to be somewhat
higher but reached no significant differences (Table 3).
The same was true for lactic acid, which showed (due to
measuring plasma) higher levels for both controls and
patients than found in capillary blood. Glutamine was
significantly lower in PKU patients as previously de-
scribed [23] and may be due to increased excretion of
N-acetylglutamine in urine (due to high phenylacetic
acid and glutamine excretion in urine). Clinical signifi-
cance of this difference is unclear. In earlier studies this
was discussed as another possible cause of mental re-
tardation in PKU siblings and may be important for the
developing brain in PKU infants (“glutamine depletion
Table 2 Significant differences of plasma lipoproteins in PKU
patients and controls (t-test). Explanation of terminology is
presented in Table S1
Lipoprotein Controls (n = 14) Patients (n = 20) p-value
Mean SD Mean SD
L2AB [mg/dL] 9.6 2.8 5.2 2.9 0.00005
L2PN [nmol/L] 173.9 51.6 93.9 53.5 0.00005
L2PL [mg/dL] 9.7 2.6 5.4 3.1 0.00007
L2CH [mg/dL] 17 5.5 8.3 6.4 0.00009
L2FC [mg/dL] 5.4 1.6 3.1 2 0.00053
L1CH [mg/dL] 24.8 3.8 18.2 6.4 0.00078
L1AB [mg/dL] 13.2 2 10.2 2.9 0.00105
L1PN [nmol/L] 239.1 36.6 185.1 53.2 0.00106
L1PL [mg/dL] 14.2 2 11.2 3 0.00115
L1FC [mg/dL] 7.4 1.3 5.6 2 0.00239
LDPL [mg/dL] 60.9 14.2 48.9 10.9 0.00368
LDCH [mg/dL] 104.1 30 79.5 21.8 0.00382
LDFC [mg/dL] 31 7.8 24.1 6.9 0.00414
L3CH [mg/dL] 14.5 7 8.6 5.6 0.0045
L3AB [mg/dL] 8.7 3.9 5.5 3.1 0.00554
L3PN [nmol/L] 158 71.6 100.6 56.1 0.00555
L3PL [mg/dL] 8.5 3.5 5.5 3 0.00579
LDPN [nmol/L] 1229.8 335.9 994.6 224 0.00815
LDAB [mg/dL] 67.6 18.5 54.7 12.3 0.00815
L3TG [mg/dL] 2.5 0.7 2 0.7 0.01909
L3FC [mg/dL] 4.6 1.7 3.3 1.8 0.0219
TPCH [mg/dL] 201 33.2 179.4 28.1 0.02204
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hypothesis” [24]). Although quality of treatment in our
patients was highly variable, most of them used amino
acid supplements, which are devoid of Phe but enriched
in tyrosine and other essential amino acids. Despite this
supplementation, tyrosine was significantly lower in
PKU patients which may contribute to neurotransmitter
depletion and impaired brain protein synthesis [1, 2, 25,
26]. No significant differences were found for branched
chain amino acids. This may be due to the number of
relatively well-treated patients in our sample (11 of 22
had Phe levels < 900 μmol/L, a value below the recom-
mended target Phe level for German adult PKU patients
[27]. Furthermore, six patients had Phe levels < 600 μmol/
Fig. 1 Correlation of plasma phenylalanine with (a) VLDL5-free
cholesterol (R = -0.5.1, p < 0.02); (b) VLDL5-triglycerides (R = -0.45,
p < 0.04); (c) VLDL5-cholesterol (R = -0.49, p < 0.02); and (d) VLDL5-
phospholipids (R = -0.49, p < 0.04). Partial correlation to BMI is
described in the text
Table 3 Results of low molecular plasma parameters in adult
PKU patients compared to controls. Significant differences were
set to p < 0.05 (t-test)
Metabolite (μmol/L) Controls (n = 14) Patients (n = 22) p-value
Mean SD Mean SD
Phenylalanine 49.2 10.1 830.7 503 0.00000
DL-Tyrosine 56.9 7.8 42.6 18.7 0.00514
Glutamine 690.6 88.4 611.4 99.1 0.01013
Glutamic acid 50.5 29.2 87.7 57.3 0.01596
Creatinine 86.1 12.7 74.8 16 0.01647
Citric acid 157.2 30.9 186.9 45.4 0.01952
3-Hydroxybutyric acid 47.6 34 83.9 102.3 0.10514
Acetoacetic acid 10.1 14.3 19.8 30 0.13468
L-Isoleucine 50.1 15.6 45.3 11.5 0.14610
Creatine 15.6 10.2 11.8 11.2 0.15723
Histidine 76.9 25.5 90.7 72 0.24784
Ethanol 107.2 55.5 117.1 45.1 0.28115
Pyruvic acid 89 38.5 96.7 38.9 0.28319
Alanine 415.5 116.5 432.8 89.7 0.31004
Trimethylamine-N-oxide 21.3 16.9 18.3 17.7 0.31144
Leucine 93.1 23.5 89.1 24.4 0.31443
Formic acid 17.5 6 16.7 4.5 0.32376
Threonine 59.8 99.2 69.5 64.2 0.36175
Acetone 23.3 10.5 21.5 18.7 0.37320
Valine 218.4 43.9 222.4 60.4 0.41777
Glycine 311.5 101.2 318.7 99.8 0.41813
Acetic acid 19.1 16 17.9 17.6 0.41959
D-Glucose 4904.1 481 4830.8 1188 0.41409
Lactic acid 2409.7 405.2 3033 1646.8 0.08787
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L, a target value recommended in the European guidelines
for PKU [28, 29]).
Chronic kidney disease (CKD) was recently discussed
as a possible comorbidity of patients with classical PKU
[30, 31]. In our patients, there was a significant differ-
ence in creatinine. The low creatinine levels may be due
to lower muscle mass [32]. Although renal functional
tests were not performed, it indicates that at least in our
patients CKD was not (yet) present.
Strengths and limitations
Our study was limited by the availability of patients’
dietary records over 3 days. Therefore, correlations to
natural protein intake could not be made and the add-
itional impact of a vegan-like diet could not be excluded.
However, our results demonstrate for the first time the
power of NMR metabolomic investigation in PKU pa-
tients in contrast to the conventional time-consuming
lipoprotein analysis as shown recently [33]. Besides im-
balances in the lipoprotein pattern revealing lower levels
of cholesterol and LDL subclasses, together with low
molecular weight analysis, this method allows a more
comprehensive monitoring of PKU patients as also dem-
onstrated in another (urinary) metabolomics approach
recently [34]. Our findings of low LDL-cholesterol and
low LDL subclass levels in these patients suggest this
may protect them from early atherosclerosis and the
lipoprotein profile is non-atherogenic. Since cardiovas-
cular comorbidities have been described by our group
and others [33, 35], it cannot be excluded that patients
may suffer from other risk factors such as type 2 dia-
betes, obesity, metabolic syndrome, or increased oxida-
tive stress caused by high Phe or the Phe-restricted low
protein diet. In addition, a possible direct effect of Phe
on the arterial wall leading to arterial stiffness was
shown recently [13, 35]. The mechanism of decreased
cholesterol and LDL lipoprotein subclasses by increased
Phe needs further investigation.
Conclusions
Using NMR spectroscopy, a unique lipoprotein profile in
PKU patients can be demonstrated which mimics a non-
atherogenic profile as seen in patients treated by statins.
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